NCT04879992

Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori

Rifabutin-containing Triple Therapy for Rescue Treatment of Helicobacter Pylori: A Randomized Clinical Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 413 (actual)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Rifabutin has good chemical stability and low drug resistance rate in acidic gastric environment. Therefore, it is often used in combination with amoxicillin proton pump inhibitor for the rescue treatment of Helicobacter pylori. The purpose of this study was to evaluate the efficacy and safety of rifabutin-containing triple therapy versus classical bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory Helicobacter pylori

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	Esomeprazole	Proton pump inhibitor
DRUG	Bismuth Potassium Citrate	Gastric mucosal protective drug with anti-H. pylori effect
DRUG	Tetracycline,Metronidazole	Antibiotics for H. pylori eradication
DRUG	amoxicillin rifabutin	Antibiotics for H. pylori eradication

Timeline

• Start date: 2021-05-07
• Primary completion: 2022-10-14
• Completion: 2022-10-30
• First posted: 2021-05-10
• Last updated: 2022-11-15

Locations

1 site across 1 country: China